449 related articles for article (PubMed ID: 16525634)
1. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
[TBL] [Abstract][Full Text] [Related]
3. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
4. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
[TBL] [Abstract][Full Text] [Related]
5. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
6. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
[TBL] [Abstract][Full Text] [Related]
8. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
9. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
10. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
[TBL] [Abstract][Full Text] [Related]
11. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
[TBL] [Abstract][Full Text] [Related]
12. AML-loaded DC generate Th1-type cellular immune responses in vitro.
Xing D; Decker WK; Li S; Robinson SN; Yang H; Segal H; O'Connor S; Yao X; Komanduri KV; McMannis JD; Jones RB; de Lima M; Champlin RE; Shpall EJ
Cytotherapy; 2006; 8(2):95-104. PubMed ID: 16698683
[TBL] [Abstract][Full Text] [Related]
13. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
14. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
[TBL] [Abstract][Full Text] [Related]
16. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
17. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.
Lee JJ; Choi BH; Kang HK; Kim SK; Nam JH; Yang DH; Kim YK; Kim HJ; Chung IJ
Leuk Res; 2008 Nov; 32(11):1653-60. PubMed ID: 18501426
[TBL] [Abstract][Full Text] [Related]
19. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.
Zhong RK; Loken M; Lane TA; Ball ED
Cytotherapy; 2006; 8(1):3-12. PubMed ID: 16627340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]